A reader, who knows how much Merck’s Gadasil Commercial, "I want to be one less woman who battles cervical cancer" trips my trigger, sent me the link to Kevin Roeten’s Blog. My issues with Gardasil have always been about an unnecessary, unsafe, outrageously expensive, drug, being … [Read more...] about Gardasil, Another Prespective
Merck
Gardasil, Future Generations Put At Risk
In Pursuit of Profit Gardasil is the first virus-like particle (VLP) based vaccine ever approved Researching Merck’s Gardasil HPV vaccine since 2005, I have read through mountains of data, reviewed medical trial results, FDA and CDC press releases, Adverse Reaction Reports, … [Read more...] about Gardasil, Future Generations Put At Risk
Can Glaxo learn from Merck
Will they absorb lessons learned from Merck’s mistakes? As Glaxo is forced to wait for FDA’s approval for its own HPV vaccine, Cervarix, will the company use its time on the sidelines to absorb lessons learned from Merck’s missteps? There is a building backlash against Merck’s … [Read more...] about Can Glaxo learn from Merck
Merck Puts Some of Their Gardasil Cash To Work
Merck to buy Schering-Plough in $41 billion deal Reported by David Jolly Publ With the purchase, Merck is expanding its franchise in cardiovascular, respiratory and oncology drugs and shoring up its research pipeline, in particular with a Schering-Plough product called TRA, a … [Read more...] about Merck Puts Some of Their Gardasil Cash To Work
Merck Execs See ‘Sage’ as Key Ingredient for Disease Biology
Will Open Source "SAGE" platform lead to more transperency to MERCK's research and clinical trials process?Consumers can only hope. Of course if MERCK corporate lawyers figure out that such an open source platform may lead to a clear chain of custody of the type of … [Read more...] about Merck Execs See ‘Sage’ as Key Ingredient for Disease Biology